According to Tempest, its options include a partnership or licensing deal, as well as a merger or an acquisition.

A clinical-stage biotech company developing first-in-class targeted and immune-mediated therapeutics to fight cancer.

The combination of bevacizumab with chemotherapy has demonstrated clinical benefit for patients with advanced non-small-cell lung cancer (NSCLC), according to a large, international, randomized ...

These issues are discussed in light of data from the BRiTE study, which indicate that the antiangiogenic effects of bevacizumab might persist despite the development of resistance to first-line ...

Biocon Biologics has received the Food and Drug Administration’s green light for Jobevne (bevacizumab-nwgd), a biosimilar bevacizumab for intravenous use. Jobevne, which is a recombinant ...

“As one small molecule, ASC30 potentially offers both ... 120 subjects in its Phase III trial of ASC40 in conjunction with bevacizumab to treat recurrent glioblastoma (rGBM).

The Company also markets Bevacizumab in Europe (approved February 2021) and Canada (approved November 2021) under the name ABEVMY. Shreehas Tambe, CEO & Managing Director, Biocon Biologics Ltd ...

Patients will receive relacorilant in combination with nab-paclitaxel and bevacizumab. "In our pivotal Phase 3 ROSELLA trial, treatment with relacorilant and nab-paclitaxel improved patients ...

JOBEVNE, a recombinant humanized monoclonal antibody used to treat several different types of cancer, is a biosimilar to the reference product Avastin ® (bevacizumab). JOBEVNE is a vascular ...